

United States of America

United States Patent and Trademark Office

N a v i g a t i o n D r u g

Reg. No. 6,720,814

Registered May 24, 2022

Corrected May 02, 2023

Int. Cl.: 1, 5, 44

Service Mark

Trademark

Principal Register

Goryo Chemical, Inc. (JAPAN CORPORATION)

EAREE Bldg. 5F,

35-100, Kita-8jo-Nishi 18-chome, Chuo-ku

Sapporo-shi, Hokkaido, JAPAN 060-0008

CLASS 1: Reagents for research purposes; reagents for chemical analyses other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis; diagnostic reagents for scientific or research use; diagnostic reagents and preparations, except for medical or veterinary use; chemicals, namely, chemicals used in industry, sulfonates, chemicals for use in agriculture, except fungicides, herbicides, insecticides and parasiticides

CLASS 5: Pharmaceutical preparations and substances for the diagnosis and treatment, and the prevention of breast, brain, colorectal and gastro-intestinal cancer; pharmaceutical preparations and substances used for detecting body fluids; pharmaceutical preparations and substances used for detecting pancreatic fluids; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cancer; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of digestive system disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of bone diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hyperlipidemia diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of gastrointestinal diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypoglycemia; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of sarcoma; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of immune system diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypertension; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of respiratory diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of skin disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of multiple sclerosis; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cardiovascular diseases; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating central nervous system disorders; diagnostic biomarker reagents for medical purposes; veterinary diagnostic reagents; fluorescent diagnostic reagents for veterinary purposes; fluorescent diagnostic test reagents for veterinary purposes; diagnostic test reagents for medical purposes; fluorescent diagnostic test reagents for medical purposes; fluorescent diagnostic reagents for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; fluorescent medical diagnostic reagents; chemical reagents for veterinary purposes; fluorescent chemical reagents for veterinary purposes; chemical reagents for medical purposes; fluorescent chemical reagents for medical purposes; reagents for medical purposes; fluorescent reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; medical

Katherine Kelly Vidal

Director of the United States
Patent and Trademark Office



diagnostic reagents and analysis samples for testing of body fluids; medical fluorescent diagnostic reagents and assays for testing of body fluids; medical fluorescent diagnostic reagents and analysis samples for testing of body fluids; medical clinical diagnostic reagents; fluorescent reagents for the clinical diagnosis; therapeutic drugs and agents, namely, agents for the treatment of malignant tumors

CLASS 44: Medical testing services using fluorescent reagents for diagnostic or treatment purposes; medical analysis services for the analysis, diagnosis, and treatment of patients using fluorescent reagents provided by medical laboratories; medical analysis for the diagnosis and treatment of persons; medical diagnostic services; medical evaluation of breast, brain, colorectal and gastro-intestinal cancer; medical diagnostic services using fluorescent reagents; medical evaluation services of breast, brain, colorectal and gastro-intestinal cancer using fluorescent reagents; diagnosis of diseases; diagnosis of diseases using fluorescent reagents; diagnosis of cancer; diagnosis of cancer using fluorescent reagents; medical testing services relating to the diagnosis and treatment of disease; medical testing services relating to the diagnosis and treatment of disease using fluorescent reagents; medical analysis services relating to the diagnosis and treatment of disease using fluorescent reagents provided by medical laboratories; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosis of cancer; cancer screening services; cancer screening services using fluorescent reagents; medical services for the analysis of samples taken from patients provided by medical laboratories; fluorescence imaging examination for the medical diagnosis or treatment; providing information in the field of cancer prevention, screening, diagnosis and treatment; providing medical information; providing medical information on diagnosis using fluorescent reagents; providing information on medical diagnosis using fluorescent reagents; medical analysis for the diagnosis of cancer using fluorescent reagents; rental of medical apparatus and installations; rental of medical diagnostic apparatus and installations; rental of medical diagnostic apparatus using fluorescent reagents and medical apparatus and installations using fluorescent reagents

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT STYLE, SIZE OR COLOR

OWNER OF INTERNATIONAL REGISTRATION 1587775 DATED 12-21-2020, EXPIRES 12-21-2030

No claim is made to the exclusive right to use the following apart from the mark as shown: "DRUG"

SER. NO. 79-309,391, FILED 12-21-2020

REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION

WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.

Requirements in the First Ten Years*

What and When to File:

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.* See 15 U.S.C. §1059.

Requirements in Successive Ten-Year Periods*

What and When to File:

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.*

Grace Period Filings*

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

***ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.

NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.